Q-omics provides the consensus-scored FBXO25 profile across patient tissues and cancer cell-line models. FBXO25 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, FBXO25 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FBXO25 RNA expression shows 18,086 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, THCA, and ACC as cancer lineages where FBXO25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO25 survival associations across molecular data types. FBXO25 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO25 RNA expression–survival associations across cancer types. High FBXO25 expression shows unfavorable associations in BLCA and STAD, but favorable associations in LGG, THYM, READ and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for FBXO25 RNA expression.
This table summarizes FBXO25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO25 shows lower tumor expression in THCA, LUAD, LUSC, BRCA and KIRC and higher tumor expression in CHOL. The THCA box plot shows higher FBXO25 RNA expression in normal versus tumor tissue (log2 FC = −0.742, t-test p < 0.001).
This table shows molecular features associated with FBXO25 in patient tissues and cancer cell lines. In patient samples, FBXO25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
